Meet one of our expert podcast guests.
CEO, NervGen Pharma Corp.
Bill is the Chief Financial Officer of NervGen Pharma Corp., a publicly-traded regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage. In his previous companies, Bill has raised over $250 million in public and private equity financing and has engaged in over $750 million in mergers and acquisition and technology licensing transactions. His experience in M&A, operations, and capital markets both in Canada and the United States has made Bill a critical asset to NervGen as it continues to build a world-class company creating new therapies for spinal cord injury and neurodegenerative diseases. Bill continues to be successful as a CFO because of his strategic mindset and integrative approach to finance.